[Expert opinion. Spironolactone: a new twist on an old story].

Orlova, Ya A; Begrambekova, Yu L; Plisuk, A G

Orlova, Ya A; Begrambekova, Yu L; Plisuk, A G.

Orlova YA; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow, Russia.
Begrambekova YL; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow, Russia.
Plisuk AG; Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow, Russia.

Kardiologiia ; 61(10): 99-103, 2021 Oct 30.

Article in Russian | MEDLINE | ID: covidwho-1515681

ABSTRACT

ABSTRACT

The article presents recent data on possibilities of a broader use of mineralocorticoid receptor antagonists for existing indications and of expanding indications for the use of this pharmaceutical group in the context of the novel coronavirus infection COVID-19. The authors discussed prospects for expanded detection of aldosteronism using a new diagnostic approach, including an additional evaluation of blood pressure response to spironolactone.

Subject(s)

COVID-19; Hypertension; Expert Testimony; Humans; Mineralocorticoid Receptor Antagonists; SARS-CoV-2; Spironolactone

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Hypertension Type of study: Experimental Studies Limits: Humans Language: Russian Journal: Kardiologiia Year: 2021 Document Type: Article Affiliation country: Cardio.2021.10.n1734

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google